Sofosbuvir/ledipasvir regimens can cost less per cure than older hepatitis C treatments
New HCV therapies unaffordable to health systems and individuals
Australia shows an alternative to rationing hepatitis C treatment
France to provide universal access to hepatitis C treatment
Only treating patients with cirrhosis with DAAs will have limited impact on HCV epidemic in England
Does having HIV affect response to hepatitis C treatment?
WHO issues new hepatitis C guidelines, EASL guidelines update forthcoming in September
